Table of Content

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Burden of Gonorrhea
4.2.2 Growing Government and Private Sector Participation Through National Campaigns
4.3 Market Restraints
4.3.1 Stringent Regulatory Scenario
4.3.2 Social Stigma Associated With Patients Visiting STD Clinics
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION
5.1 By Gonococcal Infection
5.1.1 Uncomplicated Gonococcal Infection
5.1.2 Gonococcal Arthritis
5.1.3 Gonococcal Meningitis and Endocarditis
5.2 By Treatment
5.2.1 Monotherapy
5.2.2 Dual Therapy
5.3 By End User
5.3.1 Hospital Pharmacies
5.3.2 Retail Pharmacies
5.3.3 Online Pharmacies
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East & Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Allergan, Inc.
6.1.2 F. Hoffmann-La Roche Ltd
6.1.3 GlaxoSmithKline plc
6.1.4 Lupin Pharmaceuticals
6.1.5 Pfizer Inc.
6.1.6 Teligent, Inc.


7 MARKET OPPORTUNITIES AND FUTURE TRENDS